Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial-II, most patients with SLN+ melanoma no longer un...

Descripción completa

Detalles Bibliográficos
Autores principales: Eroglu, Zeynep, Broman, Kristy K, Thompson, John F, Nijhuis, Amanda, Hieken, Tina J, Kottschade, Lisa, Farma, Jeffrey M, Hotz, Meghan, Deneve, Jeremiah, Fleming, Martin, Bartlett, Edmund K, Sharma, Avinash, Dossett, Lesly, Hughes, Tasha, Gyorki, David E, Downs, Jennifer, Karakousis, Giorgos, Song, Yun, Lee, Ann, Berman, Russell S, van Akkooi, Alexander, Stahlie, Emma, Han, Dale, Vetto, John, Beasley, Georgia, Farrow, Norma E, Hui, Jane Yuet Ching, Moncrieff, Marc, Nobes, Jenny, Baecher, Kirsten, Perez, Matthew, Lowe, Michael, Ollila, David W, Collichio, Frances A, Bagge, Roger Olofsson, Mattsson, Jan, Kroon, Hidde M, Chai, Harvey, Teras, Jyri, Sun, James, Carr, Michael J, Tandon, Ankita, Babacan, Nalan Akgul, Kim, Younchul, Naqvi, Mahrukh, Zager, Jonathan, Khushalani, Nikhil I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413295/
https://www.ncbi.nlm.nih.gov/pubmed/36002183
http://dx.doi.org/10.1136/jitc-2021-004417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413295/
https://www.ncbi.nlm.nih.gov/pubmed/36002183
http://dx.doi.org/10.1136/jitc-2021-004417

Ejemplares similares